Abstract: Interferon(IFN) is a cytokine with various biological functions, including antivirus, immuno-regulation and anti-tumor. It has been widely used in many anti-cancer therapies, including malignant melanoma, hepatocellular carcinoma, advanced renal -cell carcinoma, non-Hodgkin's lymphoma, chronic myelogenous leukemia and AIDS-related Kaposi's sarcoma.However, its effective dose is always very high, which may bring some serious side effects.Nevertheless, not all patients can benefit from the interferon therapy.In order to improve the curative effect of the interferon therapy, and lower its adverse side effects, the studies in recent years mainly focus on investigating the anti-tumor mechanism and the individualized markers of the interferon.So a problem we have faced is how to improve the efficiency and sensitivity of interferon? To solve this problem, many studies have been launched to find the effective prognostic factors and individualized biomarkers for guiding the treatment better.In addition, further clarifying the anti-tumor mechanisms of interferon is for the benefit of explaining how the biomarkers can predict prognosis of the patients.In recent studies, the expression of many interferon-related genes and proteins is not only related to the oncogenesis, but can predict the sensitivity of interferon therapy and its prognosis, such as interferon regulatory factor, IFNAR2 mRNA, microRNA and IFITM-1.Among them, some factors in the peripheral blood are of great potential in popularization of clinical practice, such as CD8highCD57+ lymphocyte levels in malignant melanoma, and serum IFNAR2 mRNA in mCRC.In this review, the advances of anti-tumorous individualized markers of interferon were briefly summarized.